dc.contributor.author | George, A | |
dc.contributor.author | Kristeleit, R | |
dc.contributor.author | Rafii, S | |
dc.contributor.author | Michie, CO | |
dc.contributor.author | Bowen, R | |
dc.contributor.author | Michalarea, V | |
dc.contributor.author | van Hagen, T | |
dc.contributor.author | Wong, M | |
dc.contributor.author | Rallis, G | |
dc.contributor.author | Molife, LR | |
dc.contributor.author | Lopez, J | |
dc.contributor.author | Banerji, U | |
dc.contributor.author | Banerjee, SN | |
dc.contributor.author | Gore, ME | |
dc.contributor.author | de Bono, JS | |
dc.contributor.author | Kaye, SB | |
dc.contributor.author | Yap, TA | |
dc.date.accessioned | 2017-05-03T14:30:40Z | |
dc.date.issued | 2017-05-01 | |
dc.identifier.citation | European journal of cancer (Oxford, England : 1990), 2017, 76 pp. 52 - 59 | |
dc.identifier.issn | 0959-8049 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/632 | |
dc.identifier.eissn | 1879-0852 | |
dc.identifier.doi | 10.1016/j.ejca.2017.01.020 | |
dc.description.abstract | Drug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available treatment options. Novel phase I trial therapies within a dedicated drug development unit may represent a viable alternative; however, there is currently little evidence for patient outcomes in such patients. To address this, we undertook a retrospective review of patients with AOC allocated to phase I trials in the Drug Development Unit at Royal Marsden Hospital (RMH) between June 1998 and October 2010. A total of 200 AOC patients with progressive disease were allocated to ≥1 trial each, with a total of 281 allocations. Of these, 135 (68%) patients commenced ≥1 trial (mean 1.4 [1-8]), totaling 216 allocated trials; 65 (32%) patients did not start due to deterioration resulting from rapidly progressive disease (63 patients) or patient choice (2 patients). Response Evaluation Criteria in Solid Tumours (RECIST) complete/partial responses (CR/PR) were observed in 43 (20%) of those starting trials, including those on poly(ADP-ribose) polymerase (PARP) inhibitors (18/79 [23%]), antiangiogenics (9/65 [14%]) and chemotherapy combinations (14/43 [33%]). Factors associated with CR/PR included: fewer prior treatments, platinum-sensitive disease, CR/PR with prior therapy, (the United States-based) Eastern Cooperative Oncology Group (ECOG) performance status score, fewer metastatic sites, higher albumin and haemoglobin levels, lower white cell counts and baseline CA125 levels, germline BRCA1/2 mutations and better RMH Prognostic Score. Mean survival was 32° months for patients who achieved CR/PR. Treatments were generally well tolerated. Most patients with AOC (134/200 [67%]) received ≥1 subsequent line of therapy after phase I trials. Our data suggest that phase I trial referrals should be considered earlier in the AOC treatment pathway and before the onset of rapid disease progression particularly with the emergence of promising novel agents in the era of precision medicine. | |
dc.format | Print-Electronic | |
dc.format.extent | 52 - 59 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCI LTD | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Carcinosarcoma | |
dc.subject | Adenocarcinoma, Clear Cell | |
dc.subject | Carcinoma, Endometrioid | |
dc.subject | Neoplasms, Cystic, Mucinous, and Serous | |
dc.subject | Granulosa Cell Tumor | |
dc.subject | Ovarian Neoplasms | |
dc.subject | Neoplasm Metastasis | |
dc.subject | Serum Albumin | |
dc.subject | Hemoglobins | |
dc.subject | Membrane Proteins | |
dc.subject | Antineoplastic Agents | |
dc.subject | CA-125 Antigen | |
dc.subject | Leukocyte Count | |
dc.subject | Prognosis | |
dc.subject | Treatment Outcome | |
dc.subject | Severity of Illness Index | |
dc.subject | Survival Rate | |
dc.subject | Retrospective Studies | |
dc.subject | Genes, BRCA1 | |
dc.subject | Genes, BRCA2 | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | England | |
dc.subject | Female | |
dc.subject | Clinical Trials, Phase I as Topic | |
dc.subject | Drug Discovery | |
dc.subject | Hereditary Breast and Ovarian Cancer Syndrome | |
dc.title | Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-01-25 | |
rioxxterms.versionofrecord | 10.1016/j.ejca.2017.01.020 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2017-05 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European journal of cancer (Oxford, England : 1990) | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Medicine Drug Development Unit (Kaye) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Medicine Drug Development Unit (Kaye) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 76 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Medicine (de Bono Prostate) | |
icr.researchteam | Clinical Pharmacology – Adaptive Therapy | |
icr.researchteam | Medicine Drug Development Unit (de Bono) | |
icr.researchteam | Prostate Cancer Targeted Therapy Group | |
icr.researchteam | Medicine Drug Development Unit (Kaye) | |
dc.contributor.icrauthor | Banerji, Udai | |